Panel · Use case · Regulatory
External Control Divergence.
LiveDivergence ReviewMap where specialists disagree on whether an external control arm can support accelerated approval, and what would settle it.
External Control Divergence is a ready-made use case for Regulatory. It ships under the Divergence Review template.
For regulatory and clinical leads. You get each seat's answer to the same question, where the positions diverge, whether each split is evidence, assumption or value, the cruxes and what would settle it. Claims are cited or marked as gaps.
Add it to your library to reuse from New → From template. Edit the saved copy in your library on the service form.
The decision
Can a single-arm trial with an external control arm support accelerated approval for a rare pediatric disease therapy?
Who is at the table
External controls are historical or concurrent data from outside the trial. Regulators have set out their concerns about them, chiefly bias from differences between the groups.
| Seat | What it is asked | What it works from |
|---|---|---|
| Regulatory Strategist | Whether the agency has accepted an external control for similar conditions and what it asked for.1,2 | FDA guidance on externally controlled trials and accelerated approval. |
| HEOR Evidence Lead | Whether payers will accept the result without a randomized comparison. | Payer assessment of single-arm evidence. |
| Global Value & Evidence Lead | Whether the external control is comparable enough, and what bias remains.1 | Natural history and registry data. |
| Clinical Operations Director | Whether a randomized trial is feasible in a rare pediatric population. | Prevalence, sites and enrollment. |
What the review does
Bias is the central worry. FDA’s guidance on externally controlled trials describes how differences in patients, care and measurement can drive results. The review shows which seat sees which risk.1
Feasibility versus certainty. In a rare pediatric disease a randomized trial may not be feasible. The review separates the disagreement about whether it is feasible, which is a matter of fact, from the disagreement about how much uncertainty to accept, which is a matter of value.2
What would settle it. A pre-specified comparability analysis agreed with the agency, and the decision it would inform.
Recommended length
Standard
Four disciplines will read this question differently. Standard depth types each divergence as evidence, assumption or value in about four pages.
You can pick another length on the form. The other two stay available.
Assumptions the review checks
The review states the assumptions each position relies on, and says what each gap limits. Examples for this question:
- The natural history data are recent enough to match current care.
- The outcome is measured the same way in the trial and in the control.
- The agency will treat the disease as having an unmet need that justifies uncertainty.
Standards, guidance and sources
Frame
The decision practice behind the memo itself is on the template page.
What gets flagged
Any claim that the agency accepted an external control for a different disease, any comparability argument that rests on one dataset, and any outcome measured differently in the two groups.
What arrives
- The question as put
- The shape of the disagreement
- Each position, in its own terms
- Where they diverge
- Why they diverge: evidence, assumption or value
- The cruxes
- What would settle it
What it will not do
It does not force a consensus, and it is a deliberation of AI specialists and not a vote of human experts. The decision stays with you.
It does not design the study or predict an agency decision.
It does not force a consensus. A report that closes every gap would be the wrong output.
It is not a vote of human experts. Every seat is an AI specialist, and the report says so.
It does not name a winner. It says what would settle the question and leaves the decision to you.
References
- [1] U.S. Food and Drug Administration. Considerations for the Design and Conduct of Externally Controlled Trials for Drug and Biological Products: draft guidance for industry. February 2023. Title and date as known from FDA’s listing; not read, and the status may have changed.
- [2] U.S. Food and Drug Administration. Expedited Programs for Serious Conditions: guidance for industry (accelerated approval). Known from FDA’s site; not read in full.
Links checked 9 October 2026
These are the sources the template drew on. None of their authors or issuers has reviewed it.
About the Panel service
Each panelist answers in their own voice, then the discussion is drawn together. You get the question and who was in the room, every position in full, what they agreed on, where they split, and what follows. Disagreements are written down rather than smoothed into a consensus nobody actually holds, because the split is usually the part you needed.
To edit a saved template, open New → Panel → From template, or the library rail on the service form.